Oppenheimer Reiterates Outperform on Pelthos Therapeutics, Raises Price Target to $57
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Oppenheimer analyst Jeff Jones reiterates Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $50 to $57.
Oppenheimer analyst Jeff Jones reiterates Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $50 to $57.
